Skip to main content
Erschienen in:

18.04.2016 | Magenkarzinom | CME

Peritonealkarzinose bei gastrointestinalen Malignomen

verfasst von: Dr. med. L. März, R. Hofheinz, P. Piso

Erschienen in: Die Onkologie | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Zusammenfassung

Als Peritonealkarzinose bezeichnet man die Besiedelung des Peritoneums mit bösartigen Zellen. Diese kann sowohl als primäre Peritonealkarzinose vom Peritoneum selbst ausgehen als auch im Sinne einer peritonealen Metastasierung als sekundäre Peritonealkarzinose auftreten. Unter den gastrointestinalen Tumoren ist das kolorektale Karzinom aufgrund der höchsten Neuerkrankungsrate der häufigste Primarius, wenngleich die Inzidenz beim Magenkarzinom mit 30 % noch höher ist. Als Mittel der Wahl zur Diagnose einer Peritonealkarzinose wird eine computertomografische Untersuchung (CT) des Abdomens (mit i. v., oraler und rektaler Kontrastmittelgabe) empfohlen. Die systemische Therapie der Peritonealkarzinose ist deutlich weniger effektiv als die von Metastasen solider Organe (z. B. Lebermetastasen). In ausgewählten Fällen ist ein operatives Verfahren mit einer vollständigen operativen Zytoreduktion (CRS) mit anschließender hyperthermer intraperitonealer Chemotherapie (HIPEC) angezeigt. Die Prognose hängt entscheidend von der Art und der Differenzierung des Primarius sowie vom Ausmaß der peritonealen Metastasierung ab und kann von wenigen Monaten bis zu mehreren Jahren reichen.
Literatur
1.
Zurück zum Zitat Chu DZ, Lang NP, Thompson C, Osteen PK, Westbrook KC (1989) Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer 63:364–367CrossRefPubMed Chu DZ, Lang NP, Thompson C, Osteen PK, Westbrook KC (1989) Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer 63:364–367CrossRefPubMed
2.
Zurück zum Zitat Segelman J, Granath F, Holm T, Machado M, Mahteme H, Martling A (2012) Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg 99:699–705CrossRefPubMed Segelman J, Granath F, Holm T, Machado M, Mahteme H, Martling A (2012) Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg 99:699–705CrossRefPubMed
3.
Zurück zum Zitat Brücher BL, Piso P, Verwaal V, Esquivel J, Derraco M, Yonemura Y, Gonzalez-Moreno S, Pelz J, Königsrainer A, Ströhlein M, Levine EA, Morris D, Bartlett D, Glehen O, Garofalo A, Nissan A (2012) Peritoneal carcinomatosis: cytoreductive surgery and HIPEC – overview and basics. Cancer Invest 30(3):209–224CrossRefPubMed Brücher BL, Piso P, Verwaal V, Esquivel J, Derraco M, Yonemura Y, Gonzalez-Moreno S, Pelz J, Königsrainer A, Ströhlein M, Levine EA, Morris D, Bartlett D, Glehen O, Garofalo A, Nissan A (2012) Peritoneal carcinomatosis: cytoreductive surgery and HIPEC – overview and basics. Cancer Invest 30(3):209–224CrossRefPubMed
4.
Zurück zum Zitat Ceelen WP, Bracke ME (2009) Peritoneal minimal residual disease in colorectal cancer: mechanisms, prevention, and treatment. Lancet Oncol 10:72–79CrossRefPubMed Ceelen WP, Bracke ME (2009) Peritoneal minimal residual disease in colorectal cancer: mechanisms, prevention, and treatment. Lancet Oncol 10:72–79CrossRefPubMed
5.
Zurück zum Zitat Piso P, Arnold D (2011) Multimodal treatment approaches for peritoneal carcinosis in colorectal cancer. Dtsch Arztebl Int 108(47):802–808PubMedPubMedCentral Piso P, Arnold D (2011) Multimodal treatment approaches for peritoneal carcinosis in colorectal cancer. Dtsch Arztebl Int 108(47):802–808PubMedPubMedCentral
6.
Zurück zum Zitat Royal RE, Pingpank JF Jr. (2008) Diagnosis and management of peritoneal carcinomatosis arising from adenocarcinoma of the colon and rectum. Semin Oncol 35(2):183–191CrossRefPubMed Royal RE, Pingpank JF Jr. (2008) Diagnosis and management of peritoneal carcinomatosis arising from adenocarcinoma of the colon and rectum. Semin Oncol 35(2):183–191CrossRefPubMed
7.
Zurück zum Zitat Simon M, Mal F, Perniceni T, Ferraz JM, Strauss C, Levard H, Louvet C, Fuks D, Gayet B (2015) Accuracy of staging laparoscopy in detecting peritoneal dissemination in patients with gastroesophageal adenocarcinoma. Dis Esophagus. doi:10.1111/dote.12332PubMed Simon M, Mal F, Perniceni T, Ferraz JM, Strauss C, Levard H, Louvet C, Fuks D, Gayet B (2015) Accuracy of staging laparoscopy in detecting peritoneal dissemination in patients with gastroesophageal adenocarcinoma. Dis Esophagus. doi:10.1111/dote.12332PubMed
8.
Zurück zum Zitat Sugarbaker PH (2015) Management of peritoneal metastases – Basic concepts. J BUON 20(Suppl 1):S2–S11PubMed Sugarbaker PH (2015) Management of peritoneal metastases – Basic concepts. J BUON 20(Suppl 1):S2–S11PubMed
9.
Zurück zum Zitat Maggiori L, Elias D (2010) Curative treatment of colorectal peritoneal carcinomatosis: current status and future trends. Eur J Surg Oncol 36(7):599–603. doi:10.1016/j.ejso.2010.05.007 Maggiori L, Elias D (2010) Curative treatment of colorectal peritoneal carcinomatosis: current status and future trends. Eur J Surg Oncol 36(7):599–603. doi:10.1016/j.ejso.2010.05.007
10.
Zurück zum Zitat Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, Pitot HC, Grothey A, Alberts SR, Sargent DJ (2012) Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol 30(3):263–267CrossRefPubMedPubMedCentral Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, Pitot HC, Grothey A, Alberts SR, Sargent DJ (2012) Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol 30(3):263–267CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Glockzin G, Rochon J, Arnold D, Lang SA, Klebl F, Zeman F, Koller M, Schlitt HJ, Piso P (2013) A prospective multicenter phase II study evaluating multimodality treatment of patients with peritonealcarcinomatosis arising from appendiceal and colorectal cancer: the COMBATAC trial. BMC Cancer 13(7):67CrossRefPubMedPubMedCentral Glockzin G, Rochon J, Arnold D, Lang SA, Klebl F, Zeman F, Koller M, Schlitt HJ, Piso P (2013) A prospective multicenter phase II study evaluating multimodality treatment of patients with peritonealcarcinomatosis arising from appendiceal and colorectal cancer: the COMBATAC trial. BMC Cancer 13(7):67CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Van Oudheusden TR, Braam HJ, Bienhuijs SW et al (2015) Poor outcome after cytoreductive surgery and HIPEC for colorectal peritoneal carcinomatosis with signet ring cell histology. J Surg Oncol 111:237–242CrossRefPubMed Van Oudheusden TR, Braam HJ, Bienhuijs SW et al (2015) Poor outcome after cytoreductive surgery and HIPEC for colorectal peritoneal carcinomatosis with signet ring cell histology. J Surg Oncol 111:237–242CrossRefPubMed
13.
Zurück zum Zitat Goere D, Souadaka A, Faron M et al (2015) Extent of colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: a comparative study. Ann Surg Oncol 22:2958–2964CrossRefPubMed Goere D, Souadaka A, Faron M et al (2015) Extent of colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: a comparative study. Ann Surg Oncol 22:2958–2964CrossRefPubMed
15.
Zurück zum Zitat Piso P, Leebmann H, März L, Mayr M (2015) Cytoreductive surgery for malignant peritoneal tumors. Chirurg 86(1):38–46CrossRefPubMed Piso P, Leebmann H, März L, Mayr M (2015) Cytoreductive surgery for malignant peritoneal tumors. Chirurg 86(1):38–46CrossRefPubMed
16.
Zurück zum Zitat Schwarz L, Votanopoulos K, Morris D et al (2015) Is the combination of distal pancreatectomy and cytoreductive surgery with HIPEC reasonable? Results of an international multicenter study. Ann Surg 263:369–375 (Epub ahead of print)CrossRef Schwarz L, Votanopoulos K, Morris D et al (2015) Is the combination of distal pancreatectomy and cytoreductive surgery with HIPEC reasonable? Results of an international multicenter study. Ann Surg 263:369–375 (Epub ahead of print)CrossRef
17.
Zurück zum Zitat Riss C, Chandrakumaran K, Dayal S et al (2015) Risk of definitive stoma after surgery forperitoneal malignancy in 958 patients: comparative study between complete cytoreductive surgery and maximal tumor debulking. Eur J Surg Oncol 41:392–395CrossRefPubMed Riss C, Chandrakumaran K, Dayal S et al (2015) Risk of definitive stoma after surgery forperitoneal malignancy in 958 patients: comparative study between complete cytoreductive surgery and maximal tumor debulking. Eur J Surg Oncol 41:392–395CrossRefPubMed
18.
Zurück zum Zitat Doud AN, Levine EA, Fino NF et al (2015) Stoma creation and reversal after cytoreductive surgery with hyperthermic intraperitoneal chemotherap. Ann Surg Oncol 23:503–510 (Epub ahead print)CrossRefPubMed Doud AN, Levine EA, Fino NF et al (2015) Stoma creation and reversal after cytoreductive surgery with hyperthermic intraperitoneal chemotherap. Ann Surg Oncol 23:503–510 (Epub ahead print)CrossRefPubMed
19.
Zurück zum Zitat Van der Speeten K, Stuart OA, Sugarbaker PH (2009) Pharmacokinetics and pharmacodynamics of perioperative cancer chemotherapy in peritoneal surface malignancy. Cancer J 15:216–224CrossRefPubMed Van der Speeten K, Stuart OA, Sugarbaker PH (2009) Pharmacokinetics and pharmacodynamics of perioperative cancer chemotherapy in peritoneal surface malignancy. Cancer J 15:216–224CrossRefPubMed
20.
Zurück zum Zitat Bhagawandin S, Naffouje S, Salti G (2015) Utility of chemoresponse assay in patients undergoing cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 22:2573–2577CrossRef Bhagawandin S, Naffouje S, Salti G (2015) Utility of chemoresponse assay in patients undergoing cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 22:2573–2577CrossRef
21.
Zurück zum Zitat Désolneux G, Mazière C, Vara J, Brouste V, Fonck M, Béchade D, Bécouarn Y, Evrard S (2015) Cytoreductive surgery of colorectal peritoneal metastases: outcomes after complete cytoreductive surgery and systemic chemotherapy only. PLOS ONE 10(3):e0122816 (eCollection 2015) doi:10.1371/journal.pone.0122816.CrossRefPubMedPubMedCentral Désolneux G, Mazière C, Vara J, Brouste V, Fonck M, Béchade D, Bécouarn Y, Evrard S (2015) Cytoreductive surgery of colorectal peritoneal metastases: outcomes after complete cytoreductive surgery and systemic chemotherapy only. PLOS ONE 10(3):e0122816 (eCollection 2015) doi:10.1371/journal.pone.0122816.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Valle SJ, Alzahrani NA, Alzahrani SE et al (2015) Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for refractory malignant ascites in patients unsuitable for cytoreductive surgery. Int J Surg 23:176–180CrossRefPubMed Valle SJ, Alzahrani NA, Alzahrani SE et al (2015) Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for refractory malignant ascites in patients unsuitable for cytoreductive surgery. Int J Surg 23:176–180CrossRefPubMed
23.
Zurück zum Zitat McConnell YJ, Mack LA, Francis WP, Ho T, Temple WJ (2013) HIPEC + EPIC versus HIPEC-alone: differences in major complications following cytoreduction surgery for peritoneal malignancy. J Surg Oncol 107(6):591–596. doi:10.1002/jso.23276. (Epub 2012 Nov 5) McConnell YJ, Mack LA, Francis WP, Ho T, Temple WJ (2013) HIPEC + EPIC versus HIPEC-alone: differences in major complications following cytoreduction surgery for peritoneal malignancy. J Surg Oncol 107(6):591–596. doi:10.1002/jso.23276. (Epub 2012 Nov 5)
24.
Zurück zum Zitat Maillet M, Glehen O, Lambert J et al (2015) Early postoperative chemotherapy after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for isolated peritoneal carcinomatosis of colon cancer: a multicenter study. Ann Surg Oncol 23:863–869 (Epub ahead of print)CrossRefPubMed Maillet M, Glehen O, Lambert J et al (2015) Early postoperative chemotherapy after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for isolated peritoneal carcinomatosis of colon cancer: a multicenter study. Ann Surg Oncol 23:863–869 (Epub ahead of print)CrossRefPubMed
25.
Zurück zum Zitat Hübner M, Teixeira H, Boussaha T et al (2015) PIPAC-pressurized intraperitoneal aerosol chemotherapy. A novel treatment for peritoneal carcinomatosis. Rev Med Suisse 11:1325–1330PubMed Hübner M, Teixeira H, Boussaha T et al (2015) PIPAC-pressurized intraperitoneal aerosol chemotherapy. A novel treatment for peritoneal carcinomatosis. Rev Med Suisse 11:1325–1330PubMed
26.
Zurück zum Zitat Pox C, Aretz S, Bischoff SC et al (2013) S3-Guideline Colorectal Cancer Version 1.0. Z Gastroenterol 51:753–854CrossRefPubMed Pox C, Aretz S, Bischoff SC et al (2013) S3-Guideline Colorectal Cancer Version 1.0. Z Gastroenterol 51:753–854CrossRefPubMed
27.
Zurück zum Zitat Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, Barone R, Yonemura Y, Cavaliere F, Quenet F (2004) Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 22:3284–3292CrossRefPubMed Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, Barone R, Yonemura Y, Cavaliere F, Quenet F (2004) Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 22:3284–3292CrossRefPubMed
28.
Zurück zum Zitat Votanopoulos KI, Russell G, Randle RW et al (2015) Peritoneal surface disease (PSD) from appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): overview of 481 cases. Ann Surg Oncol 22:1274–1279CrossRefPubMedPubMedCentral Votanopoulos KI, Russell G, Randle RW et al (2015) Peritoneal surface disease (PSD) from appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): overview of 481 cases. Ann Surg Oncol 22:1274–1279CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Dube P, Sideris L, Law C et al (2015) Guidelines on theuse of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal surface malignancy arising from colorectal or appendiceal neoplasms. Curr Oncol 22:e100–e112CrossRefPubMedPubMedCentral Dube P, Sideris L, Law C et al (2015) Guidelines on theuse of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal surface malignancy arising from colorectal or appendiceal neoplasms. Curr Oncol 22:e100–e112CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, Fontaumard E, Brachet A, Caillot JL, Faure JL, Porcheron J, Peix JL, François Y, Vignal J, Gilly FN (2000) Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 88:358–363CrossRefPubMed Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, Fontaumard E, Brachet A, Caillot JL, Faure JL, Porcheron J, Peix JL, François Y, Vignal J, Gilly FN (2000) Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 88:358–363CrossRefPubMed
Metadaten
Titel
Peritonealkarzinose bei gastrointestinalen Malignomen
verfasst von
Dr. med. L. März
R. Hofheinz
P. Piso
Publikationsdatum
18.04.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Die Onkologie / Ausgabe 5/2016
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-016-0034-4

Weitere Artikel der Ausgabe 5/2016

Der Onkologe 5/2016 Zur Ausgabe